CD73-related in vitro assays and CDK4/6, FGFR, or EGFR exon 20ins in vivo models

Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Immuno-Oncology

WuXi AppTec CD73-targeted Molecule Screening In Vitro Assays

(1) Baseline of CD73-expressing murine tumor cell lines

(2) In vitro screening assays for CD73-targeted molecules

Malachite Green (MG) colorimetric assay (PO₄^3-detection)
CellTiter-Glo (CTG) luciferase-based luminescence assay (AMP detection)

(3) In vitro MOA assays for CD73-targeted molecules

T cell & NK cell effector function evaluation
Allogeneic mixed lymphocyte reaction (MLR) assay

Translational Oncology

WuXi AppTec EGFR Exon 20 Insertion PDX Models

Lung cancer PDX model LU-01-0426 and LU-01-0493 harboring EGFR exon 20 insertion mutation, tested with Afatinib, Osimertinib or Poziotinib

Targeted Oncology

WuXi AppTec CDK4/6-related In Vivo Models

(1) CDK4/6-related CDX models, covering 7 cancer types and tested with Palbociclib, LY2835219, or LEE011

(2) CDK4/6-related PDX models, tested with Palbociclib and LY2835219

WuXi AppTec FGFR-related In Vivo Models

(2) FGFR-related PDX and PDC model list and case studies of AZD4547 on 2 PDX models

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

Best regards,

WuXi AppTec OncoWuXi Team